Who is sponsoring NCT02340676?

NCT02340676 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT02340676?

Interventions in NCT02340676: Extracorporeal Photopheresis (ECP), Interleukin-2.

What condition does NCT02340676 study?

NCT02340676 studies Chronic Graft-versus-host-disease.

Is NCT02340676 still recruiting?

NCT02340676 is currently completed. Last updated 3 February 2026.

Are results published for NCT02340676?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-02-03 · How we verify

NCT02340676

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease

Completed Phase 2 Results posted Last updated 3 February 2026

What this trial tests

Phase 2 trial testing Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-host-disease in 25 participants. Completed in 1 September 2025.

Timeline

1 February 2015

Primary endpoint
1 August 2017

1 September 2025

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	1 February 2015
Primary completion	1 August 2017
Estimated completion	1 September 2025
Sites	1 location across United States

Drugs / interventions tested

Extracorporeal Photopheresis (ECP) — full drug profile →
Interleukin-2

Conditions studied

Chronic Graft-versus-host-disease — all drugs for Chronic Graft-versus-host-disease →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, any sex, with Chronic Graft-versus-host-disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Participant With Response at Week 16
Time frame: Baseline through Week 16 of the study
Participants will have their cGVHD evaluated at baseline through Week 16.

Sponsor's own description

This research study is evaluating a combination of a therapy called Extra-corporeal Photopheresis (ECP) with a drug called Interleukin-2 (IL-2) as a possible treatment for chronic graft-versus-host-disease (GVHD) following allogeneic stem cell transplant.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanistic approaches for the prevention and treatment of chronic GVHD.
Cutler CS, Koreth J, Ritz J. · · 2017 · cited 86× · PMID 27821505 · DOI 10.1182/blood-2016-08-686659
New and emerging therapies for acute and chronic graft <i>versus</i> host disease.
Hill L, Alousi A, Kebriaei P, Mehta R, et al · · 2018 · cited 81× · PMID 29317998 · DOI 10.1177/2040620717741860
Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.
Belizaire R, Kim HT, Poryanda SJ, Mirkovic NV, et al · · 2019 · cited 31× · PMID 30936057 · DOI 10.1182/bloodadvances.2018029124
Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.
Kim HT, Koreth J, Whangbo J, Nikiforow S, et al · · 2022 · cited 16× · PMID 35617682 · DOI 10.1182/bloodadvances.2022007773
Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease.
Wobma H, Kapadia M, Kim HT, Alvarez-Calderon F, et al · · 2023 · cited 12× · PMID 37603347 · DOI 10.1182/bloodadvances.2023009729

Verify or expand the search:

Other trials of Extracorporeal Photopheresis (ECP)

Trials testing the same drug.

NCT04446182 — Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD · Phase 2 · terminated
NCT02524847 — Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory A · Phase 3 · terminated
NCT02322190 — Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of · Phase 2 · terminated

Other recruiting trials for Chronic Graft-versus-host-disease

Currently open trials in the same condition.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT06843408 — A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD · Phase 1, PHASE2 · recruiting
NCT06821542 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease Afte · Phase 3 · active not recruiting
NCT06585774 — A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease · Phase 3 · recruiting
NCT06388564 — A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia · Phase 2 · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02340676 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 3 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02340676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing